Evidence for Sequential Therapy in EGFR M+ NSCLC
Speaker: Dr. Yap Beng Khiong
Document ID: PC-MY-101296
Join Dr. Yap Beng Khiong as he brings us through the evidence for sequential therapy in EGFR M+ NSCLC. Dr Yap summarises findings from the prospective pooled analysis of the LUX-Lung trials and the GioTag study, where he highlights the rationale of sequential afatinib, followed by osimertinib therapy in the treatment of EGFR M+ NSCLC.
Speaker
Dr Yap Beng Khiong
Consultant Clinical Oncologist
MBChB, MRCP, FRCP, FRCR
Subang Jaya Medical Centre, Malaysia
Effectiveness of Dose Modification Strategies with Afatinib: A Real-World Experience
Speaker: Assoc Prof Dr Ho Gwo-Fuang
